Barclays Issues Pessimistic Forecast for Kenvue (NYSE:KVUE) Stock Price

Kenvue (NYSE:KVUE - Free Report) had its target price reduced by Barclays from $23.00 to $21.00 in a research report released on Friday morning,Benzinga reports. They currently have an equal weight rating on the stock.

A number of other brokerages also recently weighed in on KVUE. UBS Group lowered their target price on shares of Kenvue from $24.00 to $23.00 and set a "neutral" rating on the stock in a research note on Thursday. Citigroup reduced their price target on shares of Kenvue from $25.00 to $21.00 and set a "neutral" rating on the stock in a research report on Wednesday. Deutsche Bank Aktiengesellschaft cut shares of Kenvue from a "buy" rating to a "hold" rating and reduced their price target for the company from $25.00 to $24.00 in a research report on Thursday, December 12th. Royal Bank of Canada upgraded shares of Kenvue from a "hold" rating to a "moderate buy" rating in a report on Monday, December 9th. Finally, JPMorgan Chase & Co. raised their target price on shares of Kenvue from $24.00 to $25.00 and gave the stock an "overweight" rating in a report on Friday, October 11th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $23.08.

Kenvue Price Performance

Shares of NYSE:KVUE traded down $0.09 during midday trading on Friday, hitting $21.11. The stock had a trading volume of 11,266,973 shares, compared to its average volume of 8,612,558. The company has a market capitalization of $40.46 billion, a P/E ratio of 38.37, a price-to-earnings-growth ratio of 1.99 and a beta of 1.46. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The company's 50-day moving average price is $22.42 and its 200-day moving average price is $21.69. Kenvue has a fifty-two week low of $17.67 and a fifty-two week high of $24.46.

Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings results on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.27 by $0.01. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The firm had revenue of $3.90 billion for the quarter, compared to the consensus estimate of $3.92 billion. During the same quarter in the previous year, the company earned $0.31 EPS. The company's revenue for the quarter was down .4% on a year-over-year basis. As a group, equities research analysts predict that Kenvue will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th will be paid a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a yield of 3.89%. The ex-dividend date of this dividend is Wednesday, February 12th. Kenvue's dividend payout ratio (DPR) is 149.09%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. New Century Financial Group LLC purchased a new stake in Kenvue during the 4th quarter valued at approximately $323,000. Beacon Investment Advisory Services Inc. raised its stake in shares of Kenvue by 2.7% during the 4th quarter. Beacon Investment Advisory Services Inc. now owns 241,990 shares of the company's stock worth $5,166,000 after buying an additional 6,296 shares in the last quarter. First PREMIER Bank raised its stake in shares of Kenvue by 109.8% during the 4th quarter. First PREMIER Bank now owns 11,664 shares of the company's stock worth $249,000 after buying an additional 6,104 shares in the last quarter. GoalVest Advisory LLC grew its holdings in shares of Kenvue by 35.4% in the 4th quarter. GoalVest Advisory LLC now owns 94,897 shares of the company's stock worth $2,026,000 after acquiring an additional 24,835 shares during the period. Finally, Park Place Capital Corp grew its holdings in shares of Kenvue by 5.0% in the 4th quarter. Park Place Capital Corp now owns 11,930 shares of the company's stock worth $255,000 after acquiring an additional 572 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.